AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 526206: 4-sec-Butyl-2-tert-butyl-6-hydroxym ethyl-phenol

Chemical compound data from PubChem database. IUPAC Name: 4-butan-2-yl-2-tert-butyl-6-(hydroxymethyl)phenol. Molecular Formula: C15H24O2. Molecular Weight: 236.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Illinois 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.
Compound 527689: Butanoic acid, 3-chloro, 1-methylpropyl ester

Chemical compound data from PubChem database. IUPAC Name: butan-2-yl 3-chlorobutanoate. Molecular Formula: C8H15ClO2. Molecular Weight: 178.65. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530525: o-Methoxybenzoic acid, pentadecyl ester

Chemical compound data from PubChem database. IUPAC Name: pentadecyl 2-methoxybenzoate. Molecular Formula: C23H38O3. Molecular Weight: 362.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
CFSR Technical Bulletin #13A

This TB provides updates on the measurement and case review sampling framework for CFSR Round 4. The primary purpose is to announce CFSR Round 4 statewide data indicator (SWDI) national performance values. This amendment also provides other updates and clarification regarding technical aspects of measurement and sampling. A table is included in the amendment that identifies substantial changes to the original bulletin.

Metadata-only record linking to the original dataset. Open original dataset below.
New York City – 5 Boros: Drug-Related Emergency Department Visits, 2004-2011 - Suicide Attempts

Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving suicide attempts in New York City (5 boroughs), covering 2004-2011.  Drug-related suicide attempts include visits for drug overdoses and for suicide attempts by other means (e.g., using a firearm) if drugs were involved or related to the suicide attempt.
THEORY OF CHANGE: Illinois Trauma Focus Model for Reducing Long-term Foster Care

This presentation explains how the Illinois Permanecy Innovations Initiative (PII) project expects to increase rates of permanency for the target population and it describes the intervention being used, Trauma Affect Regulation: Guide for Education and Therapy (TARGET), a strength-based approach to education and therapy when youth and their families have been affected by trauma or experience a high level of stress related to adverse experiences.

Metadata-only record linking to the original dataset. Open original dataset below.
NNDSS - TABLE 1A. Anthrax to Arboviral diseases, Eastern equine encephalitis virus disease

NNDSS - Table 1A. Anthrax to Arboviral diseases, Eastern equine encephalitis virus disease - 2019. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. 

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
C.N.M.I.: Commonwealth of Northern Mariana Islands. 
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. 
† Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Compound 525623: N,N-Dimethyl-N'-decyl-p-chlorobenzamidine

Chemical compound data from PubChem database. IUPAC Name: 4-chloro-N'-decyl-N,N-dimethylbenzenecarboximidamide. Molecular Formula: C19H31ClN2. Molecular Weight: 322.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NSDUH 2019 Methodological Resource Book (MRB)

Use this collection to provide context for estimates from the 2019 National Survey on Drug Use and Health (NSDUH). This collection includes materials used to conduct the survey, reports on how the survey was conducted, and reports on how the data were processed. The Statistical Inference Report details how the data were analyzed for reports and tables, which may be useful for data users looking to do their own analysis.
Patent AT-E400176-T1: [Translated] INACTIVATED OOCYTES AS CYTOPLASMIC RECEPTORS FOR NUCLEAR TRANSFER

A method of reconstituting an animal embryo involves transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division. The oocyte is not activated at the time of transfer, so that the donor nucleus is kept exposed to the recipient cytoplasm for a period of time. The diploid nucleus can be donated by a cell in either the GO or G1 phase of the cell cycle at the time of transfer. Subsequently, the reconstituted embryo is activated. Correct ploidy is maintained during activation, for example, by incubating the reconstituted embryo in the presence of a microtubule inhibitor such as nocodazole. The reconstituted embryo may then give rise to one or more live animal births. The invention is useful in the production of transgenic animals as well as non-transgenics of high genetic merit.
Compound 529996: Heptadecane, 9-ethyl-8-methyl

Chemical compound data from PubChem database. IUPAC Name: 9-ethyl-8-methylheptadecane. Molecular Formula: C20H42. Molecular Weight: 282.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Variation in red cell transfusion practice in the intensive care unit: a multicentre cohort study

Objectives:
          To determine the degree of interinstitutional transfusion practice variation and reasons why red cells are administered in critically ill patients.
        
        
          Study design:
          Multicentre cohort study combined with a cross-sectional survey of physicians requesting red cell transfusions for patients in the cohort.
        
        
          Study population:
          The cohort included 5298 consecutive patients admitted to six tertiary level intensive care units in addition to administering a survey to 223 physicians requesting red cell transfusions in these units.
        
        
          Measurements:
          Haemoglobin concentrations were collected, along with the number and reasons for red cell transfusions plus demographic, diagnostic, disease severity (APACHE II score), intensive care unit (ICU) mortality and lengths of stay in the ICU.
        
        
          Results:
          Twenty five per cent of the critically ill patients in the cohort study received red cell transfusions. The overall number of transfusions per patient-day in the ICU averaged 0.95 ± 1.39 and ranged from 0.82 ± 1.69 to 1.08 ± 1.27 between institutions (P < 0.001). Independent predictors of transfusion thresholds (pre-transfusion haemoglobin concentrations) included patient age, admission APACHE II score and the institution (P < 0.0001). A very significant institution effect (P < 0.0001) persisted even after multivariate adjustments for age, APACHE II score and within four diagnostic categories (cardiovascular disease, respiratory failure, major surgery and trauma) (P < 0.0001). The evaluation of transfusion practice using the bedside survey documented that 35% (202 of 576) of pre-transfusion haemoglobin concentrations were in the range of 95-105 g/l and 80% of the orders were for two packed cell units. The most frequent reasons for administering red cells were acute bleeding (35%) and the augmentation of O2 delivery (25%).
        
        
          Conclusions:
          There is significant institutional variation in critical care transfusion practice, many intensivists adhering to a 100g/l threshold, and opting to administer multiple units despite published guidelines to the contrary. There is a need for prospective studies to define optimal practice in the critically ill.
TNF-α induced endothelial MAdCAM-1 expression is regulated by exogenous, not endogenous nitric oxide

Background
          MAdCAM-1 is an adhesion molecule expressed in Peyer's patches and lymphoid tissues which is mobilized by cytokines like TNF-α and is a major determinant of lymphocyte trafficking to the gut in human inflammatory bowel disease (IBD). It has been suggested that both reactive oxygen and nitrogen metabolites participate in regulating adhesion molecule expression in response to TNF-α.
        
        
          Methods
          To examine how exogenous and endogenous sources of NO modulate MAdCAM-1 induction by TNF-α, we pre-treated mouse lymphatic endothelial cells with either long or short acting NO donors prior to TNF-α-stimulation, and measured MAdCAM-1 induction at 24 h.
        
        
          Results and Discussion
          DETA-NO, a long-acting NO donor, and SperNO, a rapid releasing NO donor both inhibited TNF-α-stimulated MAdCAM-1 expression in a concentration dependent manner. Both NO donors also reduced a4b7-dependent lymphocyte endothelial adhesion. Inhibition of endogenous NO production by either L-NAME, a non-selective NOS inhibitor, or by 1400 w, a selective iNOS inhibitor failed to induce, or potentiate TNF-α regulated MAdCAM-1 expression.
        
        
          Conclusions
          Exogenous NO donors may be beneficial in the treatment of IBD, while endogenous nitric oxide synthases may be less effective in controlling adhesion molecule expression in response to cytokines.
Compound 528000: 3-Methylbutan-2-yl 3,5-dinitrobenzoate

Chemical compound data from PubChem database. IUPAC Name: 3-methylbutan-2-yl 3,5-dinitrobenzoate. Molecular Formula: C12H14N2O6. Molecular Weight: 282.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Hospital Cost Report Audited Data: 2012

This version of the Institutional Cost Report (ICR) has been audited by a Certified Public Accounting Firm. The ICR is a uniform report completed by New York State hospitals to report income, expenses, assets, liabilities, and statistics to the the Department of Health (DOH). Under DOH regulations, (Part 86-1.2), Article 28 hospitals are required to file financial and statistical data with DOH annually. The data filed is part of the ICR and is received electronically through a secured network. This data is used to develop Medicaid rates, assist in the formulation of reimbursement methodologies, and analyze trends. For more information, check out: http://www.health.ny.gov/facilities/hospital/index.htm.
Parkinson’s Disease Biomarkers Program Data Management Resource (PDBP DMR)

<p>The NINDS Parkinson’s Disease (PD) Biomarkers Program Data Management Resource enables web-based data entry for clinical studies supporting PD biomarker development, as well as broad data sharing (imaging, clinical, genetic, and biospecimen analysis) across the entire PD research community. The PDBP DMR coordinates information and access to PD biospecimens distributed through the NINDS Human Genetics, DNA, iPSC , Cell Line and Biospecimen Repository and the Harvard Neurodiscovery Initiative.</p>
Compound 527676: Butanoic acid, 2-chloro, 1-methylethyl ester

Chemical compound data from PubChem database. IUPAC Name: propan-2-yl 2-chlorobutanoate. Molecular Formula: C7H13ClO2. Molecular Weight: 164.63. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400492-T1: [Translated] FUNCTIONAL PEDAL MECHANICS

The present invention relates to a pedal mechanism for use in a bicycle, ergometer or other therapy, rehabilitation or fitness device for active and/or passive bending and stretching of the legs or for carrying out combined movement sequences that include this movement. The pedal mechanism substantially comprises a support ( 19 ) and a shoe support ( 15 ) that is movably arranged on the support ( 19 ). The support ( 19 ) is rotatably arranged on a pedal shaft ( 17 ) by means of the bearing sleeves ( 21 ). The pedal shaft ( 17 ) is non-rotatably connected to a sleeve ( 23 ). The sleeve ( 23 ) has a guide groove ( 25 ) in which a cam arranged on the shoe support ( 15 ) engages. When the pedal shaft ( 17 ) is rotated relative to the shoe support ( 15 ) the shoe support ( 15 ) is swivelled.
Compound 529328: Furan-2-carboxaldehyde, 3-methyl

Chemical compound data from PubChem database. IUPAC Name: 2-methylcyclopenta-1,3-diene-1-carbaldehyde. Molecular Formula: C7H8O. Molecular Weight: 108.14. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530697: 2,3,4-Trifluorobenzoic acid, 2,7-dimethyloct-7-en-5-yn-4-yl ester

Chemical compound data from PubChem database. IUPAC Name: 2,7-dimethyloct-7-en-5-yn-4-yl 2,3,4-trifluorobenzoate. Molecular Formula: C17H17F3O2. Molecular Weight: 310.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
IgVH genes from different anatomical regions, with different
		  histopathological patterns, of a rheumatoid arthritis patient suggest cyclic
		  re-entry of mature synovial B-cells in the hypermutation process

In the present study 55 IgVH genes amplified from three different
			 anatomical regions of a rheumatoid arthritis (RA) patient were analyzed, adding
			 further information on synovial B-cell maturation and recirculation in RA. This
			 analysis demonstrated somatically mutated IgVh genes in all regions studied,
			 with amino acid deletions and mixed IgVh molecules, suggesting the existence of
			 a novel pathway to generate (auto) antibody specificities. Comparison of amino
			 acid sequences of amplified genes that belong to the VH1 family (with
			 predominantly the same germline counterpart) exhibited strong homology,
			 indicating an apparently conserved mutational pattern. This suggests that the
			 number of antigens that activate B cells in different locations is restricted.
			 The most striking result was the finding of clonally related sequences in
			 different anatomical regions, indicating a recirculation of activated B cells
			 between the different affected joints.
Brief report on the effect of providing single versus assorted brand name condoms to hospital patients: a descriptive study

Objectives
          This study examined condom acquisition by persons in a hospital setting when single versus assorted brand name condoms were provided.
        
        
          Methods
          Condom receptacles were placed in exam rooms of two clinics. During Phase 1, a single brand name was provided; for Phase 2, assorted brand names were added. Number of condoms taken was recorded for each phase.
        
        
          Results
          For one clinic there was nearly a two-fold increase in number of condoms taken (Phase 1 to Phase 2); for the second clinic there was negligible difference in number of condoms taken.
        
        
          Conclusions
          The provision of assorted brand name condoms, over a single brand name, can serve to increase condom acquisition. Locations of condoms and target population characteristics are related factors.
Patent AT-E400105-T1: [Translated] METHOD FOR SYNCHRONIZATION IN A LOCAL NETWORK USING A STORAGE AND FORWARDING DEVICE

The present invention relates to a method for identifying inaccurate time measurements in a local area network. The local area network comprises a sending device (2), such as a time client, a destination device (3), such as a timeserver, and a switching device and/or a store-and-forward device (6). A time request packet (4) is rejected if it arrives at the time client or timeserver within a given or calculated minimum distance from the preceding network packet. The time request packet (4) is also rejected if it falls outside a set of calculated error limits based on a set of estimates. Those estimates are kept in the time client memory and updated according to a given set of rules.
Compound 528161: Methyl 1-(4-chlorobenzoyl)-5-methoxy-2-methylindole-3-carboxylate

Chemical compound data from PubChem database. IUPAC Name: methyl 1-(4-chlorobenzoyl)-5-methoxy-2-methylindole-3-carboxylate. Molecular Formula: C19H16ClNO4. Molecular Weight: 357.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Agency for Healthcare Research and Quality (AHRQ) Patient Safety Indicator 11 (PSI-11) Measure Rates

The Agency for Healthcare Research and Quality (AHRQ) Patient Safety Indicator 11 (PSI-11) Measure Rates dataset provides information on provider-level measure rates regarding one preventable complication (postoperative respiratory failure) for Medicare fee-for-service discharges. The PSI-11 measure data is solely reported for providers’ information and quality improvement purposes and are not a part of the Deficit Reduction Act (DRA) Hospital-Acquired Condition (HAC) Payment Provision or HAC Reduction Program.
Compound 529650: ent-16-Kauren-19-ol

Chemical compound data from PubChem database. IUPAC Name: (5,9-dimethyl-14-methylidene-5-tetracyclo[11.2.1.01,10.04,9]hexadecanyl)methanol. Molecular Formula: C20H32O. Molecular Weight: 288.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
A modification of Representational Difference Analysis, with application to the cloning of a candidate in the Reelin signalling pathway

Background
          cDNA-RDA is one of the subtractive cloning techniques used to isolate differentially expressed genes between two complex cDNA populations. In the present study we present a modification of the protocol described by Hubank and Schatz.
        
        
          Results
          In the post-hybridization mix, the 5'-ends of homoduplexes of interest (tester-tester) are filled-in with α-thio-deoxynucleotides. Unprotected duplexes, as well as the single-stranded DNA fragments, are degraded using ExoIII and Mung Bean Nuclease, prior to PCR subtraction, resulting in less complex difference products. We illustrate this modification by the cloning of a new gene which is differentially expressed in normal, reelin and Dab1 mutant mice and is a candidate member of the Reelin signalling pathway involved in brain development.
        
        
          Conclusion
          We propose a modification of cDNA-RDA that may reduce the complexity of the post-hybridization mix and thus facilitate the amplification of differentially expressed products.
2010 State Profile — Utah

This state profile includes data from facilities in Utah that reported to N-SSATS for the survey reference date March 31, 2010. Data were collected on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (both public and private) in Utah. In Utah, 146 substance abuse treatment facilities were included in the 2010 N-SSATS, reporting that there were 12,993 clients in substance abuse treatment on March 31, 2010. The survey response rate in Utah was 97.5%.
Compound 526555: 2,5,8,11,14,17,20-Heptaoxadocosan-22-ol

Chemical compound data from PubChem database. IUPAC Name: 2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol. Molecular Formula: C15H32O8. Molecular Weight: 340.41. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.